Bausch + Lomb Corporation

Toronto Stock Exchange BLCO.TO

Bausch + Lomb Corporation EBITDA for the year ending December 31, 2023: USD 499.00 M

Bausch + Lomb Corporation EBITDA is USD 499.00 M for the year ending December 31, 2023, a -16.69% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • Bausch + Lomb Corporation EBITDA for the year ending December 31, 2022 was USD 599.00 M, a -21.39% change year over year.
  • Bausch + Lomb Corporation EBITDA for the year ending December 31, 2021 was USD 762.00 M, a 3.11% change year over year.
  • Bausch + Lomb Corporation EBITDA for the year ending December 31, 2020 was USD 739.00 M, a -21.05% change year over year.
  • Bausch + Lomb Corporation EBITDA for the year ending December 31, 2019 was USD 936.00 M, a 1.52% change year over year.
Key data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)
Market news
Loading...
Toronto Stock Exchange: BLCO.TO

Bausch + Lomb Corporation

CEO Mr. Brenton L. Saunders J.D.
IPO Date May 6, 2022
Location Canada
Headquarters 520 Applewood Crescent
Employees 13,000
Sector Consumer Discretionary
Industries
Description

Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.

Similar companies

PET.TO

Pet Valu Holdings Ltd.

USD 18.36

3.15%

DNTL.TO

dentalcorp Holdings Ltd.

USD 5.48

-0.17%

BHC.TO

Bausch Health Companies Inc.

USD 7.49

1.16%

StockViz Staff

January 15, 2025

Any question? Send us an email